TenQ · Stock reportUpdated 2026-10-16

Novavax (NVAX)

$1.9B market cap · TenQ Score 9/36

Makes protein-based vaccines, with its Covid vaccine now sold through Sanofi.

$11.26close as of 2026-10-16
+32.8% over 1Y · 16.0 points ahead of the S&P 500
$5.69$7.61$9.52$11.43$13.35Oct '25Dec '25Mar '26May '26Aug '26Oct '26

“Can growing Matrix-M demand and Sanofi royalties sustain Novavax between milestone payments?”

Editorial note · updated 2026-10-08
The TenQ Radar

Novavax in 36 checks

Novavax on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.

VALUEGROWTHQUALITYFINANCIAL HEALTHSHAREHOLDERRETURNSTREND

The business itself is the question here: 9 of 36 checks passed.

The Novavax story

What drives Novavax, what its price assumes and what could change the story, written from its own filings.

  • Product demand improved. In the quarter to June 2026, product sales rose 76% to $19 million, but total revenue fell 76% to $57 million against a comparison boosted by milestone payments.
  • Commercial costs declined. In the quarter to June 2026, SG&A expenses declined 39% to $27 million as Novavax transferred lead commercial activities to Sanofi and reduced its administrative costs.
  • Sanofi timing matters. Initiation of Sanofi's Phase 3 COVID-19 and influenza combination trial in the U.S. or European Union would trigger a $125 million payment, but regulatory discussions on timing remained underway in August 2026.

Read the Novavax story

Advertisement
Latest earnings

Novavax's latest earnings

Q2 '26 · quarter to 30 June 2026 · reported 6 August 2026 · Earnings release ↗

Revenue$57M-76%vs 2025-59%vs Q1
Earnings-$53M-$160Mvs 2025-$44Mvs Q1
What the release says

The earnings summary is free with an account.

Sign up free to read it

AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q

Earnings alerts

An email when Novavax reports, with its results and highlights. Free with a watchlist account.

I

Value

●●●●●●1/6

Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.

-no history
4.5xown 10-year median 11.0x
-2.3%cash earned per $ of price
-whole-business multiple
Valuation history

Is NVAX's P/E, P/S or P/B high or low against its own past?

→At 4.5x sales, the market is paying 59% less than NVAX's own 10-year median of 11.0x. Pessimism is priced in - the question is whether it is deserved.

What this measures

What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.

What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.

If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.

Free cash flow yield

What is NVAX's free cash flow yield at today's price?

→Every dollar of market value currently buys -2.3% of annual free cash flow, less than its 10-year median of -19.1% - you are paying up for the same cash.

What this measures

Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.

What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.

If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.

What does “Value” actually mean?

Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.

How we scored it · 1 of 6 checks passed
✓Cheaper than its own history (sales - not yet profitable)4.49 vs 11.01
✕Cheap on sales (under 2.5x)4.49 vs 2.50 (fixed yardstick)
✕Cheap on enterprise value vs sales (under 3x)3.45 vs 3.00 (fixed yardstick)
✕Free cash flow yield above 3%FCF yield -2.3%
✕Cheap on enterprise value (under 14x EBITDA)no EBITDA to value: -$216M over the last twelve months
✕Priced for less growth than its record suggestsnot profitable: no free cash flow or earnings for the price to rest on
II

Growth

●●●●●●0/6

Growth is weak or inconsistent. The trend, not the story, is the problem.

-61.6%vs the year before
-17.2%compound annual
-158.6%net income growth
-compound annual
Revenue history

Is NVAX's revenue growing?

◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)

→Revenue reached $1.1B in 2025, compounding -17% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $414M, behind the last full year.

What this measures

The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.

What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.

If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.

Revenue by regionInsight

Where does Novavax's revenue come from?

This insight is free with an account.

Sign up free to see it

→Novavax makes 68% of its revenue from United States ($38M), and that share has risen from -7% in 2024Q1: the mix is shifting towards United States.

Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30

Profit history

Is NVAX's net profit growing?

◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)

→Net income was $440M in 2025, against -$187M the year before. Earnings per share moved -159% over the last twelve months. Trailing twelve-month profit stands at -$248M.

What this measures

What is left after every cost, including tax and interest. The bottom line of the income statement.

What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.

If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.

Growth rate

How fast are NVAX's revenue and earnings growing?

→Revenue fell 62% over the twelve months to 2026-06-30, against an average of +40% a year over 2021-2025.

What this measures

How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.

What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.

If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.

Per-share growth

Are NVAX's revenue and free cash flow per share growing?

→Revenue per share reached $6.49 in 2025, compounding -37% a year against -17% for NVAX as a whole. Dilution absorbed about 19.3 points of that growth. The trailing twelve months are running at $2.39 a share. Free cash flow per share stands at $-1.45.

What this measures

Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.

What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.

If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.

What does “Growth” actually mean?

Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).

How we scored it · 0 of 6 checks passed
✕Outgrew its sector over the last twelve months-61.6% vs 20.4% (sector 70th pct, n=256)
✕Sustained growth beats its sector (3 years)-17.2% vs 18.5% (sector 70th pct, n=251)
✕Profits grew over the last twelve months-158.6% vs 0.0%
✕Profit growth beats its peers (3 years)loss-making: TTM net income -$248M
✕Growth is speeding up, not slowinglast twelve months -61.6% vs three-year pace -17.2%
✕Grew per share, not just in total-74.4% vs 0.0%
III

Quality

●●●●●●1/6

Profitability is thin or negative. The growth isn't turning into money yet.

78.6%kept after direct costs
-56.6%kept after running costs
-profit on shareholders' money
-37.5%against a 10% cost of capital
-operating cash ÷ net income
Margins

What profit margin does NVAX keep on each sale?

→Operating margin widened 73 points to 40% since 2022. After everything, 39 cents of each sales dollar reaches net profit.

What this measures

What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.

What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.

If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.

Earnings quality

Does NVAX's operating cash flow keep up with its profit?

→The company generated -$245M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.

What this measures

Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.

What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.

If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.

Returns on capital

What return on equity and on capital does NVAX earn?

→ROE of -60% and ROCE of -37% sit close together, so the returns come from the business itself rather than from borrowing.

What this measures

Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).

What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.

If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.

Income waterfall

Where does NVAX's revenue go, from sales to net profit?

→Of $414M over the twelve months to 2026-06-30 sales, nothing reaches the bottom line - the journey from revenue to profit ends $248M underwater.

What this measures

One year of revenue, with each major cost taken out in the order the income statement takes it, ending at net profit.

What good looks like. No single step swallowing a surprising share, and a bottom line that survives all of them.

If it rises or falls. The largest step is where the business really spends its money, and it is the one to watch year to year: a step that grows faster than revenue is what margin compression looks like before it reaches the margin chart.

Cash conversion

How much of each sale does NVAX turn into free cash flow?

→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.

What this measures

Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.

What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.

If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.

Spending intensity

How much of its revenue does NVAX spend on capex, R&D and stock pay?

→The biggest claim on each sales dollar is research and development, at 30% of revenue (stock compensation 3%, capital spending 0%). That share has fallen since 2022, so the cost of competing is easing.

What this measures

Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.

What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.

If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.

Customer concentrationInsight

How much of Novavax's revenue comes from its largest customers?

This insight is free with an account.

Sign up free to see it

→Government of Canada and Sanofi made up 87% of Novavax's revenue in FY2025. Government of Canada alone made up 51%, up from 10% in FY2022.

Source: SEC filings: customer concentration notes (XBRL) · as at 2026-06-30

Return on capital employed

Is NVAX's return on capital above what its capital costs?

→NVAX earns 63.2% on the capital it employs, well above the 10% most investors treat as the cost of capital. That is the highest in NVAX's filed history.

What this measures

The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.

What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.

If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.

What does “Quality” actually mean?

Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.

How we scored it · 1 of 6 checks passed
✓Better gross margins than its sector78.6% vs 58.1% (sector 70th pct, n=113)
✕Runs leaner than its sector (operating margin)-56.6% vs 10.5% (sector 70th pct, n=252)
✕Actually profitableTTM net income -$248M
✕Earns well on shareholders' moneynegative equity
✕Earns a real return on the capital it employs-37.5% vs 10.0%
✕Generates cash despite the lossTTM operating cash flow -$37M on a net loss of $248M
IV

Financial health

●●●●●●2/6

The balance sheet carries real risk. Read the checks before anything else.

-debt unreported
2.3xnear-term bills coverage
-16xearnings ÷ interest bill
$719Mcash plus short-term investments
Debt & cash

How much debt does NVAX carry, and do its profits cover the interest?

→The company holds $719M in cash against $291M of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.

What this measures

Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.

What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.

If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.

Near-term liquidity

Do NVAX's current assets cover the bills due within a year?

→Near-term liquidity is comfortable: 2.3x of current assets for every dollar due within the year. That is thinner than in 2011.

What this measures

Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.

What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.

If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.

Interest cover

How many times over can NVAX's operating profit pay its interest bill?

→Operating profit does not cover the interest bill (-16.1x). Cover is wider than in 2011.

What this measures

Operating profit divided by interest expense - how many times over the year's earnings could pay the year's interest.

What good looks like. High and steady. Five times is a common floor; comfortably above it means the debt is being carried, not merely serviced.

If it rises or falls. It falls when profit falls or when borrowing costs rise, and a company can look safe on the level while the direction is telling you otherwise.

Cash conversion

How much of NVAX's revenue arrives as operating cash?

→NVAX's operations consumed cash rather than produced it over the last twelve months. Up from -160.9% in 2011.

What this measures

Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.

What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.

If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.

Shareholders' equity

Is NVAX's shareholder equity (book value) growing?

Equity is below zero after years of buybacks exceeding earnings, so debt-to-equity and return on equity are not published for NVAX: a ratio to a negative base means nothing.

→Shareholders' equity is negative at -$191M: liabilities exceed assets. Usually the mark of heavy buybacks or accumulated losses, and always worth understanding which.

What this measures

What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.

What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.

If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.

What does “Health” actually mean?

Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.

How we scored it · 2 of 6 checks passed
✓Comfortable near-term liquidity2.33 vs 1.50
✕Debt isn't dominatingnegative equity
✕Debt trending the right wayliabilities are 120.0% of assets vs 113.6% five years ago
✕Earnings cover the interest-16.09 vs 5.00
✕Converts sales to cash better than its sector-8.9% vs 14.4% (sector 70th pct, n=274)
✓Self-funding17.05 years of cash at current burn
V

Shareholder returns

●●●●●●0/6

NVAX returns nothing to shareholders yet, and the share count keeps rising. Every dollar stays in the business.

-bought back, TTM, over market value
-at the current rate
-dividends plus buybacks
$32Mlast 12m, dilutes the buybacks
+2829.7%since 2011 (split-adjusted)
Share count change (split-adjusted)

Is NVAX's share count rising or falling?

→The share count grew 13.7% in 2025, averaging 31.2% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.

What this measures

The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.

What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.

If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.

Dilution against what it bought

Has NVAX's revenue per share grown faster than its share count?

Change since 2011. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.

→NVAX's share count rose 2939% from 2011 to 2025 while revenue per share grew 152%. Holders are further ahead than before, though the gain per share is smaller than the growth in the business.

What this measures

The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.

What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.

If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.

Why compare buybacks with stock compensation?

A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.

How we scored it · 0 of 6 checks passed
✕Share count isn't climbingshares up 121.4% over 3 years
✕Buybacks outpace the stock issued to staffno buybacks against $32M of stock compensation
✕Hands cash back to ownersno dividends and no buybacks in the last twelve months
✕Meaningful yield to owners (dividends and buybacks)0.00 returned, 0.0% of market value
✕Buybacks are sustained, not one-offpays no dividend and reports no buybacks
✕Buybacks growingpays no dividend and reports no buybacks
VI

Trend

●●●●●●5/6

A confirmed uptrend: above the cloud, above both trend lines, and the readings agree.

+23.0%the long-term trend line
+42.9%S&P 500 (SPY): +3.1%
+26.4%S&P 500 (SPY): +16.0%
-12.2%drawdown from peak
Trend

Which way is NVAX's share price trending?

Price chart loads as you scroll…

Chart by TradingView

→NVAX is in a clear uptrend: the price is above the cloud where recent trading settled, and that cloud is still rising underneath it. The last two weeks and the month-ago comparison both point up, so the shorter readings back the trend.

How the trend above is worked out

The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.

How we scored it · 5 of 6 checks passed
✓Price above the Kumo cloud$11.26 against a cloud top of $9.48
✕Price above the Tenkan and the Kijun$11.26 against the Tenkan (9 sessions) at $12.05 and the Kijun (26) at $11.27
✓Tenkan above the KijunTenkan $12.05 above the Kijun $11.27, 42 sessions since they crossed
✓The Senkou cloud ahead is risingthe Senkou spans already drawn for the next 26 sessions are rising
✓Chikou above the price 26 sessions back$11.26 against $9.30 26 sessions ago
✓Beating the S&P 500 over 12 months26.4% vs 16.0%
VII

Insider activity

informational
$0.00their own money
$0.00often pre-scheduled
0of the last filings
60grants · exercises · tax
Open-market flow

Are NVAX's insiders buying or selling shares with their own money?

→Since November 2023, insiders sold $1M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 112 transactions were grants, option exercises or tax withholding, which say nothing either way.

What this measures

Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.

What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.

If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.

The record

Who did what, exactly?

DateInsiderRoleTypeSharesPriceValue
2026-03-07James Patrick KellyEVP, CFO and Treasurertax5,904$9.98$58,922
2026-03-03James Patrick KellyEVP, CFO and Treasurertax20,850$9.49$197,867
2026-03-03John C JacobsPresident and CEOtax69,288$9.49$657,543
2026-03-03Elaine O'HaraEVP, Chief Strategy Officertax22,429$9.49$212,851
2026-03-03Mark J CaseyEVP, Chief Legal Officertax11,378$9.49$107,977
2026-03-03Ruxandra Draghia-AkliEVP, Research & Developmenttax11,313$9.49$107,360
2026-03-01John C JacobsPresident and CEOtax38,450$10.14$389,883
2026-03-01James Patrick KellyEVP, CFO and Treasurertax28,366$10.14$287,631
2026-03-01Elaine O'HaraEVP, Chief Strategy Officertax5,375$10.14$54,503
2026-03-01Elaine O'HaraEVP, Chief Strategy Officertax10,969$10.14$111,226
Why do the transaction types matter so much?

Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.

VIII

Ownership

informational
71.2%on Form 13F, 30 June 2026
0.7%officers, directors, founders
48.1%together
Top holders

Who owns Novavax stock?

Fund managers filing Form 13F held 71.2% of the company's shares on 30 June 2026. The largest holder is Shah Capital Management, with 8.6%. Insiders hold 0.7%.

#HolderStakeSharesValueChange
1Shah Capital ManagementFund manager8.59%14.2M$160M-4.6%
2BlackRock, Inc.Fund manager8.46%13.9M$157M+8.6%
3State Street CorpFund manager7.12%11.7M$132M+30.9%

The full list of top holders is free with an account

Sign up free

Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.

Where does this list come from?

Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.

§

Recent filings

A short weekly note on what changed in the numbers, coming soon.One email a week: the charts that mattered, nothing else.
Where these numbers come from. Financial statements: US SEC EDGAR (XBRL company facts, as filed - including restatements; hatched chart bars are fourth quarters derived from annual filings), current to 2026-06-30. Prices: delayed end-of-day, as of 2026-10-16. Scores are counts of the transparent pass/fail checks shown in each chapter; every sentence on this page is computed from the data shown, except the labelled editorial note. Missing data is shown as missing, never estimated. Nothing here is investment advice. Terms · Methodology